See more : Steven Madden, Ltd. (SHOO) Income Statement Analysis – Financial Results
Complete financial analysis of Otonomy, Inc. (OTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Otonomy, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vecima Networks Inc. (VCM.TO) Income Statement Analysis – Financial Results
- Gold Fields Limited (GFI) Income Statement Analysis – Financial Results
- H-One Co.,Ltd. (5989.T) Income Statement Analysis – Financial Results
- SOFTRAK VENTURE INVESTMENT LTD (SOFTRAKV.BO) Income Statement Analysis – Financial Results
- Playmates Toys Limited (0869.HK) Income Statement Analysis – Financial Results
Otonomy, Inc. (OTIC)
About Otonomy, Inc.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 273.00K | 600.00K | 745.00K | 1.24M | 683.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 370.00K | 1.19M | 912.00K | 946.00K | 3.10M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -915.00K | -312.00K | -201.00K | -1.86M | -981.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -196.00% | -335.16% | -52.00% | -26.98% | -150.65% | -143.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 34.67M | 28.00M | 32.81M | 31.84M | 42.70M | 60.72M | 38.76M | 31.80M | 16.34M | 8.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.58M | 11.69M | 20.01M | 46.84M | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Other Expenses | 0.00 | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | -14.00K | 3.71M |
| Operating Expenses | 49.38M | 42.57M | 44.50M | 51.85M | 89.54M | 110.50M | 61.98M | 39.64M | 19.85M | 10.93M |
| Cost & Expenses | 49.75M | 43.76M | 45.41M | 52.80M | 92.64M | 112.16M | 61.98M | 39.64M | 19.85M | 10.93M |
| Interest Income | 43.00K | 326.00K | 1.72M | 1.69M | 1.27M | 899.00K | 419.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 1.57M | 1.59M | 4.00K | 0.00 | 0.00 | 0.00 | 39.00K | 2.53M | 444.00K |
| Depreciation & Amortization | 856.00K | 1.06M | 1.15M | 1.19M | 1.29M | 708.00K | 358.00K | 213.00K | 257.00K | 192.00K |
| EBITDA | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.61M | -7.03M |
| EBITDA Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.85M | -10.93M |
| Operating Income Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.56M | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | 291.00K | 3.36M |
| Income Before Tax | -51.18M | -44.73M | -44.68M | -50.37M | -90.13M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Income Before Tax Ratio | -40,944.80% | -16,384.98% | -7,445.83% | -6,760.81% | -7,292.07% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -856.00K | -1.06M | -1.15M | -1.19M | -1.29M | -708.00K | -358.00K | -213.00K | 2.51M | 4.15M |
| Net Income | -50.33M | -43.67M | -43.53M | -49.18M | -88.84M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Net Income Ratio | -40,260.00% | -15,995.97% | -7,254.33% | -6,601.61% | -7,187.78% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| EPS Diluted | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| Weighted Avg Shares Out | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
| Weighted Avg Shares Out (Dil) | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
Otonomy stock loses half its value after disappointing trial results of vertigo treatment
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
Otonomy, Inc. (OTIC) CEO David Weber on Q4 2020 Results - Earnings Call Transcript
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
Otonomy to Participate in Two Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports